Docusign Envelope ID: F516E6E4-0E6A-85FE-812F-698A1BB01E82 603 Page 1 of 3 15 July 2001 Form 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme CLARITY PHARMACEUTICALS LTD ACN/ARSN 143 005 341 1. Details of substantial holder (1) Retail Employees...
Becoming a substantial holder
Filed with ASX · · 6 pages · English
Release
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- First FDA Breakthrough Therapy designation in PSMA PET
- Ceasing to be a substantial holder
- Trading Halt
- Pause in Trading
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Clarity Pharmaceuticals
All Clarity Pharmaceuticals news releasesFollow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals